Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma
Authors:
- Daniel J. ZabranskyDZDaniel J. Zabransky
- Emma KartaliaEKEmma Kartalia
- Jae W. LeeJLJae W. Lee
- James M. LeathermanJLJames M. Leatherman
- Soren CharmsazSCSoren Charmsaz
- Sara E. YoungSYSara E. Young
- Yash ChhabraYCYash Chhabra
- Sebastià Franch-ExpósitoSebastià Franch-Expósito
- Martin KangMKMartin Kang
- Saumya MaruSMSaumya Maru
- 3 December 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 82 (3) , 599-611
Abstract
Background and Aims: Isocitrate dehydrogenase 1 (IDH1)-mutant cholangiocarcinoma (CCA) is a highly lethal subtype of hepatobiliary cancer that is often resistant to immune checkpoint inhibitor therapies. We evaluated the effects of IDH1 mutations in CCA cells on the tumor immune microenvironment and identified opportunities for therapeutic intervention. Approach and Results: Analysis of 2606 human CCA tumors using deconvolution of RNA-sequencing data identified decreased CD8+ T cell and increased M2-like tumor-associated macrophage (TAM) infiltration in IDH1-mutant compared to IDH1 wild-type tumors. To model the tumor immune microenvironment of IDH1-mutant CCA in vivo, we generated an isogenic cell line panel of mouse SB1 CCA cells containing a heterozygous IDH1 R132C (SB1mIDH1) or control (SB1WT) mutation using CRISPR-mediated homology-directed repair. SB1mIDH1 cells recapitulated features of human IDH1-mutant CCA including D-2-hydroxyglutarate production and increased M2-like TAM infiltration. SB1mIDH1 cells and tumors produced increased levels of CCL2, a chemokine involved in the recruitment and polarization of M2-like TAMs, compared to wild-type controls. In vivo neutralization of CCL2 led to decreased M2-like TAM infiltration, reduced tumor size, and improved overall survival in mice harboring SB1mIDH1 tumors. Conclusions: IDH1-mutant CCA is characterized by an increased abundance of M2-like TAMs. Targeting CCL2 remodels the tumor immune microenvironment and improves outcomes in preclinical models of IDH1-mutant CCA, highlighting the role of myeloid-targeted immunotherapies in the treatment of this cancer.Keywords
This publication has 51 references indexed in Scilit:
- Profiling of syngeneic mouse HCC tumor models as a framework to understand anti–PD‐1 sensitive tumor microenvironmentsHepatology, 2023
- Biology of IDH mutant cholangiocarcinomaHepatology, 2022
- Tumor-associated macrophages in cholangiocarcinoma: complex interplay and potential therapeutic targetEBioMedicine, 2021
- Anti–PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in MiceCellular and Molecular Gastroenterology and Hepatology, 2021
- Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 studyThe Lancet Oncology, 2020
- Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant CancersACS Medicinal Chemistry Letters, 2018
- Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular ProfilesCell Reports, 2017
- D-2-Hydroxyglutarate does not mimic all the IDH mutation effects, in particular the reduced etoposide-triggered apoptosis mediated by an alteration in mitochondrial NADHCell Death & Disease, 2015
- Sequence signatures and mRNA concentration can explain two‐thirds of protein abundance variation in a human cell lineMolecular Systems Biology, 2010
- High-level JAG1 mRNA and protein predict poor outcome in breast cancerLaboratory Investigation, 2007